Episode
E360: The Hardest Lessons I Learned from Building 4 Unicorns
- Published
- May 1, 2026
- Duration seconds
- 3253
- Processing state
not_requested- Canonical source
- https://howiinvestpodcast.com/episodes/62g30ivlLYm
Actions
POST https://stenobird.com/v1/public/podcasts/how-i-invest-with-david-weisburd-6470713/episodes/e360-the-hardest-lessons-i-learned-from-building-4-unicorns/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/how-i-invest-with-david-weisburd-6470713/e360-the-hardest-lessons-i-learned-from-building-4-unicorns.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
What if the biggest breakthroughs in biotech don’t come from more capital—but from building better systems for innovation? In this episode, I sit down with Errik Anderson, biotech entrepreneur and founder behind multiple billion-dollar companies, to discuss how building infrastructure, not just drugs, is reshaping the future of healthcare. Errik explains why most biotech companies fail the same way, how reducing the cost and time of experimentation unlocks more innovation, and why staying private longer enables better long-term decision making. We also explore compounding in biotech, the limits of scaling creativity, and how conviction, mission, and talent ultimately determine which companies change the world.